Connect with us

Technology

REPLY: COVU Transforms Customer Experience with Amazon Connect, Partnering with Storm Reply

Published

on

CHICAGO, Nov. 7, 2024 /PRNewswire/ — Storm Reply, an AWS Premier Consulting Partner and member of the Reply network, has successfully implemented Amazon Connect for COVU, a leader in AI-native services for insurance agencies. This integration empowers COVU to enhance its customer experience, scale operations with a growing number of AI solutions, and drive business growth with a robust and flexible contact center platform.

COVU’s contact center, the core of its operations, manages customer calls, text messages, web inquiries, and emails for numerous client agencies. As the company grew, COVU sought to replace its legacy system, which had limitations in visibility and call management. To further elevate its telephony capabilities, gain deeper insights into essential metrics like average wait times and abandonment rates, and build a foundation for rapidly developing new AI solutions, COVU partnered with Storm Reply to implement Amazon Connect, a cloud-based contact center system.

Storm Reply implemented several AI-driven features, including real-time call transcription, automated redaction of personally identifiable information (PII), and AI-powered call summaries. Additionally, sentiment analysis was integrated to help agents and supervisors proactively manage customer satisfaction.

Since implementing Amazon Connect, COVU has boosted efficiency and scalability, using AI-driven insights to handle more interactions without raising costs. Enhanced call routing and real-time insights have cut call abandonment rates by 20% and helped meet service level agreements, setting the stage for scalable growth. The integration of AWS telephony and SMS technology has further positioned COVU to quickly expand its AI capabilities, including the development of an AI voice agent that answers calls when human agents are busy, and creates tickets for operations staff, enhancing service efficiency. As a result, agent satisfaction has increased by over 250%.

Amin Zarshenas, Cofounder and Chief Product Officer at COVU  shared, “With Amazon Connect’s ability to seamlessly integrate with other AI services, we are poised to quickly launch new AI applications, drive operational efficiencies to foster business growth, and ensure success for our clients. This shift allows my leadership team and me to move beyond operational challenges and focus on strategic initiatives that fuel our company’s growth.”

Don Mishory, Managing Partner at Storm Reply, added, “By implementing Amazon Connect, we’ve empowered COVU to achieve remarkable efficiency and scalability. With AI-driven insights and advanced call routing, COVU has enhanced customer interactions while keeping operational costs steady. The integration of AWS technology has also paved the way for innovative solutions like an AI voice agent, significantly improving service efficiency and agent experience.”

Learn more about how COVU enhanced its customer experience here.

Reply

Reply [EXM, STAR: REY] specializes in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialized companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organizations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Storm Reply

Storm Reply is a global leader in cloud-based solutions and services, specializing in the design and implementation of innovative Cloud infrastructures. As an AWS Premier Consulting Partner, Storm Reply supports businesses in implementing cloud systems, including Infrastructure as a Service (IaaS), Software as a Service (SaaS), and Platform as a Service (PaaS). Storm Reply helps enterprises leverage the cloud to drive business transformation and growth.

COVU

COVU is a tech-enabled partner for independent insurance agencies, offering an AI-powered platform that combines advanced technology with licensed support staff, market access, and expert advice. COVU’s all-in-one solution helps insurance agencies focus on strategic growth, improve customer service, and future-proof their operations.

Press contact:

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Anusha Shankar
a.shankar@reply.com
Tel. +1 3129980306

View original content to download multimedia:https://www.prnewswire.com/news-releases/reply-covu-transforms-customer-experience-with-amazon-connect-partnering-with-storm-reply-302298256.html

SOURCE Reply

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Cryoport Reports Third Quarter 2024 Financial Results

Published

on

By

Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024Company reaffirmed full year 2024 revenue guidance of $225 to $235 million

NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. 

Jerrell Shelton, CEO of Cryoport, remarked, “Our Life Sciences Services business showed 9% growth during the third quarter, with BioStorage/BioServices revenue increasing by 12% compared to the third quarter of last year. The increase in our services revenue was coupled with a substantial improvement in gross margin to 46% for our services business.

“Reflecting on our performance through the third quarter, we are maintaining our full-year revenue forecast of $225 million to $235 million, anticipating continued growth in our services business while acknowledging the ongoing softness in product sales.

“We have been actively executing on our cost reduction and capital realignment strategies and we are currently on course to complete these adjustments by the year’s end. These actions are already showing positive results, as evidenced by the improvement in our gross margin, adjusted EBITDA and positive cash flow this quarter, moving us closer towards our objective of sustainable profitability. We believe that these measures will lead us to a return to positive adjusted EBITDA during 2025.

“We expect the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue for the near future, so we plan to further sharpen our focus on profitable growth and maintaining a strong balance sheet. We continue to be optimistic about our long-term business growth trajectory. We believe that we are strategically positioned to leverage the anticipated long-term growth in the Life Sciences and the Cell & Gene Therapy market through our comprehensive and integrated supply chain solutions.

“In October, we launched our IntegriCell™ Cryopreservation Solution with a new state-of-the-art facility on our Houston campus. This offering addresses yet another critical aspect in optimizing the supply chain for the development and commercialization of cell-based therapies through high quality, standardized, cryopreserved starting material,” Mr. Shelton concluded.

In tabular form, Q3 2024 and 9M 2024 revenue compared to Q3 2023 and 9M 2023, respectively, was as follows:

Cryoport, Inc. and Subsidiaries

Revenue 

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

(in thousands)

2024

2023

% Change

2024

2023

% Change

Life Sciences Services

$       39,278

$       36,022

9 %

$     114,104

$     107,062

7 %

BioLogistics Solutions

35,302

32,486

9 %

103,076

97,093

6 %

BioStorage/BioServices 

3,976

3,536

12 %

11,028

9,969

11 %

Life Sciences Products

$       17,386

$       20,135

-14 %

$       54,749

$       68,933

-21 %

Total Revenue

$       56,664

$       56,157

1 %

$     168,853

$     175,995

-4 %

 

BioStorage/BioServices revenue continues to grow double digits year-over-year, increasing 12%, as we continue to introduce our expanded capabilities to existing customers as well as add new customers into our global network, and as more allogeneic clinical and commercial therapies progress in the number of patients treated.

Revenue from commercially approved Cell & Gene therapies represented $6.1 million, or 11%, of total revenue for Q3 2024. During Q3 2024, one new therapy was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, which was SanBio’s AKUUGO, an allogeneic treatment for the indication of improving chronic motor paralysis resulting from traumatic brain injury. In addition, the FDA approved Adaptimmune’s Tecelra for the treatment of adults with unresectable or metastatic synovial sarcoma, the first cell therapy targeting a solid tumor. Our total commercial therapy count was seventeen (17) as of September 30, 2024.

As of September 30, 2024, Cryoport supported a total of 691 global clinical trials, a net increase of 21 clinical trials over September 30, 2023, with 79 trials in Phase 3. The number of trials by phase and region are as follows: 

Cryoport Supported Clinical Trials by Phase

Clinical Trials

September 30,

2022

2023

2024

Phase 1

268

275

295

Phase 2

295

314

317

Phase 3

80

81

79

Total

643

670

691

Cryoport Supported Clinical Trials by Region

Clinical Trials

September 30,

2022

2023

2024

Americas

496

516

531

EMEA

105

112

112

APAC

42

42

48

Total

643

670

691

  

During the third quarter, three (3) Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings occurred, and one (1) BLA filing occurred in October. For the remainder of 2024, we anticipate up to an additional four (4) application filings and two (2) new therapy approvals, with another two (2) possible approvals of new therapies in January of 2025.

BioLogistics Solutions revenue rose 9% year over year during the third quarter as it continued to benefit from the ramp in temperature-controlled logistics revenue outside of the Cell & Gene therapy market, including biosimilars, antibodies, APIs and a growing number of Direct-to-Patient shipments.

Financial Highlights

Revenue

Total revenue for Q3 2024 was $56.7 million compared to $56.2 million for Q3 2023, a year-over-year increase of 1% or $0.5 million. Life Sciences Services revenue for Q3 2024 was $39.3 million compared to $36.0 million for Q3 2023, up 9.0% year-over-year and 3.3% sequentially, including BioStorage/BioServices revenue of $4.0 million, up 12.4% year-over-year and 12.9% sequentially. Life Sciences Products revenue for Q3 2024 was $17.4 million compared to $20.1 million for Q3 2023, down 13.7% year-over-year and 11.1% sequentially.Total revenue for 9M 2024 was $168.9 million compared to $176.0 million for 9M 2023. Life Sciences Services revenue for 9M 2024 was $114.1 million compared to $107.1 million for 9M 2023, including BioStorage/BioServices revenue of $11.0 million for 9M 2024 compared to $10.0 million for 9M 2023.Life Sciences Products revenue for 9M 2024 was $54.7 million compared to $68.9 million for 9M 2023.

Gross Margin

Total gross margin was 44.8% for Q3 2024 compared to 43.2% for Q3 2023. Gross margin for Life Sciences Services was 46.0% for Q3 2024 compared to 42.2% for Q3 2023. Gross margin for Life Sciences Products was 42.1% for Q3 2024 compared to 44.9% for Q3 2023.Total gross margin was 42.8% for 9M 2024 compared to 43.2% for 9M 2023. Gross margin for Life Sciences Services was 44.0% for 9M 2024 compared to 44.1% for 9M 2023. Gross margin for Life Sciences Products was 40.5% for 9M 2024 compared to 41.9% for 9M 2023.

Operating Costs and Expenses

Operating costs and expenses were $41.8 million for Q3 2024 compared to operating costs and expenses of $41.2 million for Q3 2023. Operating costs and expenses for 9M 2024 were $189.3 million compared to $121.4 million for 9M 2023. The operating costs and expenses for 9M 2024 include an impairment loss of $63.8 million recorded in Q2 2024, which is primarily related to the write off of remaining goodwill for MVE Biological Solutions.

Net Income (Loss)

Net income was $0.8 million for Q3 2024 compared to a net loss of $13.3 million for Q3 2023, which was primarily a result of increased gains on the extinguishment of debt. Net loss was $96.1 million for 9M 2024 compared to a net loss of $37.2 million for the same period in 2023, which was primarily a result of the impairment loss of $63.8 million recorded in Q2 2024.Net loss attributable to common stockholders was $1.2 million, or $0.02 per share, and $102.1 million, or $2.07 per share, for Q3 2024 and 9M 2024, respectively. This compares to a net loss attributable to common stockholders of $15.3 million, or $0.31 per share, and $43.2 million, or $0.89 per share, for Q3 2023 and 9M 2023, respectively.

Adjusted EBITDA

Adjusted EBITDA was a negative $2.4 million for Q3 2024, compared to a negative $3.1 million for Q3 2023. Adjusted EBITDA for 9M 2024 was a negative $13.9 million, compared to a negative $1.7 million for 9M 2023.

Cash, Cash equivalents, and Short-Term Investments

Cryoport held $272.7 million in cash, cash equivalents, and short-term investments as of September 30, 2024.

Convertible Debt repurchases

In Q3 2024, the Company announced that its Board of Directors had authorized a repurchase program to purchase up to $200.0 million of the Company’s common stock and/or convertible senior notes (the “2024 Repurchase Program”), which was in addition to the remaining amount under its 2022 repurchase program. The 2024 Repurchase Program became effective on August 1, 2024, and remains in effect through December 31, 2027. The Company has approximately $73.9 million in total of repurchase authorization available under its two Repurchase Programs as of September 30, 2024.During Q3 2024, the Company repurchased $175.0 million in aggregate principal amount of its Convertible Senior Notes due in 2026 for an aggregate repurchase price of $154.5 million.

Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Outlook

The Company reaffirms full year 2024 revenue guidance in the range of $225 million$235 million. The Company’s 2024 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of our control, such as the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, and the effects of foreign currency fluctuations, as well as the other factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

Additional Information

Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which is expected to be filed with the SEC on November 7, 2024. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport’s website at www.cryoportinc.com.

Earnings Conference Call Information

IMPORTANT INFORMATION: In addition to the earnings release, a document titled “Cryoport Third Quarter 2024 in Review”, providing a review of Cryoport’s financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thursday, November 7, 2024. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on November 7, 2024. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference Call Information

Date:

Thursday, November 7, 2024

Time:

5:00 p.m. ET

Dial-in numbers:

1-800-717-1738 (U.S.), 1-646-307-1865 (International)

Confirmation code:

Request the “Cryoport Call” or Conference ID: 1171580

Live webcast:

‘Investor Relations’ section at www.cryoportinc.com or click here.

 

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company’s website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until November 14, 2024. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1171580#.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to conduct their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are “Enabling the Future of Medicine™” worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.

Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport’s intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport’s industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport’s outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport’s plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport’s clients. Forward-looking statements also include those related to Cryoport’s anticipation of continued growth in its services business and ongoing softness in product sales; Cryoport’s plans and expectations relating to its previously announced cost reduction and capital realignment strategies, including Cryoport’s plans to complete these adjustments by the year’s end and Cryoport’s belief that these measures will lead to a return to positive adjusted EBITDA during 2025; Cryoport’s expectations that the macroeconomic and sector-specific challenges that have impacted many companies serving the life sciences industry to continue into the near future; and Cryoport’s belief that it is strategically positioned to leverage the anticipated long-term growth in the Cell & Gene therapy market through Cryoport’s comprehensive and integrated supply chain solutions. It is important to note that Cryoport’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport’s cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties include difficulties, delays or Cryoport’s inability to successfully complete its planned cost reduction and capital realignment measures, which could reduce the benefits realized from such activities within the time periods currently anticipated. Cryoport’s business could be affected by other factors discussed in Cryoport’s SEC reports, including in the “Risk Factors” section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three Months Ended
September 30,
(unaudited)

Nine Months Ended
September 30,
(unaudited)

(in thousands, except share and per share data)

2024

2023

2024

2023

Revenue

Life Sciences Services revenue

$              39,278

$              36,022

$            114,104

$            107,062

Life Sciences Products revenue

17,386

20,135

54,749

68,933

Total revenue

56,664

56,157

168,853

175,995

Cost of revenue:

Cost of services revenue

21,220

20,803

63,927

59,887

Cost of products revenue

10,059

11,088

32,576

40,037

Total cost of revenue

31,279

31,891

96,503

99,924

Gross margin

25,385

24,266

72,350

76,071

Operating costs and expenses:

Selling, general and administrative

37,654

36,023

111,921

108,066

Engineering and development

4,157

5,152

13,555

13,291

Impairment loss

63,809

Total operating costs and expenses:

41,811

41,175

189,285

121,357

Loss from operations

(16,426)

(16,909)

(116,935)

(45,286)

Other income (expense):

Investment income

3,059

2,848

8,468

7,962

Interest expense

(889)

(1,357)

(3,472)

(4,197)

Gain on extinguishment of debt, net

17,326

5,679

18,505

5,679

Other income (expense), net

(1,616)

(3,059)

(1,398)

242

Income (loss) before provision for income taxes

1,454

(12,798)

(94,832)

(35,600)

Provision for income taxes

(649)

(471)

(1,247)

(1,598)

Net income (loss)

$                    805

$             (13,269)

$             (96,079)

$             (37,198)

Paid-in-kind dividend on Series C convertible preferred stock

(2,000)

(2,000)

(6,000)

(6,000)

Net loss attributable to common stockholders

$               (1,195)

$             (15,269)

$          (102,079)

$             (43,198)

Net loss per share attributable to common stockholders – basic and diluted

$                 (0.02)

$                 (0.31)

$                 (2.07)

$                 (0.89)

Weighted average common shares outstanding – basic and diluted

49,417,757

48,904,102

49,261,717

48,660,646

 

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

September 30,

December 31,

2024

2023

(in thousands)

(unaudited)

Current assets

Cash and cash equivalents

$                      44,665

$                      46,346

Short-term investments

228,001

410,409

Accounts receivable, net

43,461

42,074

Inventories

23,552

26,206

Prepaid expenses and other current assets

10,658

10,077

Total current assets

350,337

535,112

Property and equipment, net

88,281

84,858

Operating lease right-of-use assets

30,113

32,653

Intangible assets, net

175,815

194,382

Goodwill

54,057

108,403

Deposits

1,493

1,680

Deferred tax assets

1,669

656

 Total assets 

$                    701,765

$                    957,744

Current liabilities

Accounts payable and other accrued expenses

$                      25,194

$                      26,995

Accrued compensation and related expenses

11,275

11,409

Deferred revenue

1,091

1,308

Current portion of operating lease liabilities

5,834

5,371

Current portion of finance lease liabilities

470

286

Current portion of convertible senior notes, net

14,271

Current portion of notes payable

153

149

Current portion of contingent consideration

3,151

92

Total current liabilities

61,439

45,610

Convertible senior notes, net

183,628

378,553

Notes payable, net

1,238

1,335

Operating lease liabilities, net

26,466

29,355

Finance lease liabilities, net

1,306

954

Deferred tax liabilities

3,526

2,816

Other long-term liabilities

569

601

Contingent consideration, net

5,021

9,497

    Total liabilities

283,193

468,721

    Total stockholders’ equity

418,572

489,023

    Total liabilities and stockholders’ equity

$                    701,765

$                    957,744

 

Note Regarding Use of Non-GAAP Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 are included in this release: revenue at constant currency, revenue growth rate at constant currency, operating costs and expenses, excluding impairment loss, net income, excluding impairment loss, and adjusted EBITDA. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including revenue at constant currency, revenue growth rate at constant currency and adjusted EBITDA, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

We believe that revenue growth is a key indicator of how Cryoport is progressing from period to period, and we believe that the non-GAAP financial measures, revenue at constant currency and revenue growth rate at constant currency, are useful to investors in analyzing the underlying trends in revenue. Under GAAP, revenue received in local (non-U.S. dollar) currency is translated into U.S. dollars at the average exchange rate for the period presented. As a result, fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities, which in turn may adversely affect results of operations and cash flows and the comparability of period-to-period results of operations. When we use the term “constant currency,” it means that we have translated local currency revenue for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenue into U.S. dollars that we used to translate local currency revenue for the comparable reporting period of the prior year. Revenue growth rate at constant currency refers to the measure of comparing the current reporting period revenue at constant currency with the reported GAAP revenue for the comparable reporting period of the prior year.

However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both period-over-period changes in non-GAAP constant currency revenue on the one hand and changes in revenue prepared in accordance with GAAP on the other. We caution the readers of this press release to follow a similar approach by considering revenue on constant currency period-over-period changes only in addition to, and not as a substitute for, or superior to, changes in revenue prepared in accordance with GAAP.

Operating costs and expenses, excluding impairment loss, is defined as operating costs and expenses, excluding impairment losses, if any. Net loss, excluding impairment loss, is defined as net loss, excluding impairment losses, if any. Management believes these measures, when read in conjunction with, and as supplemental to, the corresponding GAAP financial measures, provide a useful measure of Cryoport’s expenses and operating results, a meaningful comparison with historical results, and insight into Cryoport’s operating performance.

Adjusted EBITDA is defined as net loss adjusted for interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency (gain)/loss, gain on insurance claim, net gain on extinguishment of debt, impairment loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA provides a useful measure of Cryoport’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport’s ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA to gain a better understanding of Cryoport’s comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA, when read in conjunction with Cryoport’s GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport’s ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport’s underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport’s underlying business.

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP operating cost and expenses to Non-GAAP adjusted operating cost and expenses

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2024

2023

2024

2023

(in thousands)

GAAP operating costs and expenses

$        41,811

$             41,175

$      189,285

$      121,357

Non-GAAP adjustments to operating costs and expenses

Impairment loss

63,809

Non-GAAP adjusted operating costs and expenses

$        41,811

$             41,175

$      125,476

$      121,357

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2024

2023

2024

2023

(in thousands)

GAAP net income (loss)

$              805

$           (13,269)

$      (96,079)

$      (37,198)

Non-GAAP adjustments to net income (loss)

Impairment loss

63,809

Non-GAAP adjusted net income (loss)

$              805

$           (13,269)

$      (32,270)

$      (37,198)

 

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP net income (loss) to adjusted EBITDA

(unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2024

2023

2024

2023

(in thousands)

GAAP net income (loss)

$              805

$      (13,269)

$      (96,079)

$      (37,198)

Non-GAAP adjustments to net income (loss):

Depreciation and amortization expense

7,836

6,911

22,863

20,038

Acquisition and integration costs

308

675

896

6,304

Cost reduction initiatives

568

1,116

Investment income

(3,059)

(2,848)

(8,468)

(7,962)

Unrealized loss on investments

3,535

2,336

2,593

2,300

Gain on insurance claim

(2,642)

Foreign currency (gain)/loss

(1,724)

710

(762)

114

Interest expense, net

889

1,357

3,472

4,197

Stock-based compensation expense

4,838

5,976

15,291

16,960

Gain on extinguishment of debt, net

(17,326)

(5,679)

(18,505)

(5,679)

Impairment loss

63,809

Change in fair value of contingent consideration

316

250

(1,329)

250

Other non-recurring costs

Income taxes

649

471

1,247

1,598

Adjusted EBITDA

$         (2,365)

$         (3,110)

$      (13,856)

$         (1,720)

 

Cryoport, Inc. and Subsidiaries

Total revenue by type for the three months ended September 30, 2024

(unaudited)

Life Sciences
Services

Life Sciences
Products

Total

(in thousands)

As Reported

$             39,278

$                17,386

$             56,664

Non US-GAAP Constant Currency

39,193

17,340

56,532

FX Impact [$]

85

46

132

FX Impact [%]

0.2 %

0.3 %

0.2 %

Cryoport, Inc. and Subsidiaries

Total revenue by type for the nine months ended September 30, 2024

(unaudited)

Life Sciences
Services

Life Sciences
Products

Total

(in thousands)

As Reported

$           114,104

$                54,749

$           168,853

Non US-GAAP Constant Currency

114,220

54,774

168,994

FX Impact [$]

(116)

(25)

(141)

FX Impact [%]

(0.1 %)

(0.0 %)

(0.1 %)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-third-quarter-2024-financial-results-302299246.html

SOURCE Cryoport, Inc.

Continue Reading

Technology

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Published

on

By

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidance

ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ — Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024.

“We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again raising our full-year guidance,” said Bryan Hanson, chief executive officer, Solventum. “It has been an exciting start, and we are confident that our three-phased approach will drive long-term growth and significant value creation.”

Third Quarter 2024 Financial Results

3 months ended September 30, 2024

(Millions of dollars, except per share amounts)

GAAP

non-GAAP1

Sales

$2,082

$2,082

Operating income

$275

$475

Operating income margin

13.2 %

22.8 %

Earnings per share (EPS)

$0.70

$1.64

Cash from operations/free cash flow1

$169

$76

Reported and organic sales growth reflect the expected normalization of pricing. By segment, organic sales growth was primarily driven by the MedSurg and Health Information Systems segments, partially offset by the Dental Solutions and Purification and Filtration segments. 

GAAP and adjusted operating income margin declined due to lower gross margins, including the impact from the 3M supply agreement mark-up, and an increase in operating expenses related to public company stand-up costs and growth investments.

1 Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.

 

Segment and Total Company Net Sales for Third Quarter*

Three months ended
September 30

Increase/(Decrease)

(Dollars in millions)

2024

2023

Total

Currency
Impact

Other2

Organic

MedSurg

$          1,182

$          1,180

0.1 %

(0.1) %

(0.7) %

1.0 %

Dental Solutions

313

331

(5.2)

(1.2)

(3.9)

Health Information Systems

326

321

1.5

0.1

1.5

Purification and Filtration

238

242

(1.5)

(1.1)

(0.3)

Corporate and Unallocated3

23

NM

NM

NM

NM

Total Company

$          2,082

$          2,074

0.4 %

(0.1) %

0.2 %

0.3 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

2Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Divestiture impacts include lost sales from the company’s dental anesthetics business that was sold in August 2023 and certain health care businesses retained by 3M India in connection with the spin-off.

3Corporate and unallocated includes sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the company at spin-off.

Full-Year 2024 Guidance
Solventum is raising its full-year 2024 guidance

Organic sales growth to the upper half of 0% to +1.0% (previously 0% to +1.0%)Adjusted EPS of $6.50 to $6.65 (previously $6.30 to $6.50)Free cash flow of $750M to $850M (previously $700M to $800M)

Organic sales, adjusted EPS and free cash flow amounts included in Solventum’s full-year guidance and additional considerations below are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. 

Solventum’s full-year 2024 guidance is based on Q1 2024 as a carve-out plus the remainder of the year as a stand-alone company starting April 1, 2024.

See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.

Earnings Conference Call
Solventum will host a conference call today, November 7, at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.

A replay of the webcast, along with the earnings press release, slides highlighting the results, and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the company’s website.

Forward-Looking Statement
This news release contains forward-looking information about Solventum’s financial results and estimates and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum’s control; (2) operational execution risks; (3) damage to Solventum’s reputation or its brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) Solventum’s business dealings involving third-party partners in various markets; (6) Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers’ research budgets or government funding; (10) the timing and market acceptance of Solventum’s new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to per-and polyfluoroalkyl substances; (16) risks related to the highly regulated environment in which Solventum operates; (17) climate change and measures to address climate change; (18) security breaches and other disruptions to information technology infrastructure; (19) Solventum’s failure to obtain, maintain, protect, or effectively enforce its intellectual property rights; (20) pension and postretirement obligation liabilities; (21) any events that adversely affect the sale or profitability of one of Solventum’s key products or the revenue delivered from sales to its key customers; (22) any failure by 3M Company (“3M“) to perform any of its obligations under the various separation agreements entered into in connection with the separation of Solventum from 3M and distribution (the “Spin-Off”); (23) any failure to realize the expected benefits of the Spin-Off; (24) Solventum’s ability to execute its turnaround strategy; (25) a determination by the IRS or other tax authorities that the Separation or certain related transactions should be treated as taxable transactions; (26) indebtedness incurred in the financing transactions undertaken in connection with the Separation and risks associated with additional indebtedness; (27) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum’s estimates; and (28) the impact of the Spin-Off on Solventum’s businesses and the risk that the separation from 3M may be more difficult, time-consuming or costly than expected, including the impact on Solventum’s resources, systems, procedures and controls, diversion of management’s attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in Solventum’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

Non-GAAP Financial Measures
In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted earnings per share, and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP. 

The Q3 2024 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers’ toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com

Solventum Corporation

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME

(Dollars in millions, except per-share amounts)

(Unaudited)

Three months ended
September 30,

Nine months ended
September 30,

2024

2023

2024

2023

Net sales of product

$       1,608

$       1,593

$       4,766

$       4,750

Net sales of software and rentals

474

481

1,413

1,411

Total net sales

2,082

2,074

6,179

6,161

Cost of product

793

748

2,341

2,262

Cost of software and rentals

124

117

364

364

Gross profit

1,165

1,209

3,474

3,535

Selling, general and administrative expenses

701

525

1,998

1,681

Research and development expenses

189

180

576

568

Total operating expenses

1,807

1,570

5,279

4,875

Operating income

275

504

900

1,286

Interest expense, net

107

260

Other expense (income), net

1

4

48

10

Income before income taxes

167

500

592

1,276

Provision for income taxes

45

40

144

202

Net Income

$          122

$          460

$          448

$       1,074

Earnings per share:

Basic earnings per share

$         0.70

$         2.66

$         2.59

$         6.22

Diluted earnings per share

0.70

2.66

2.58

6.22

Weighted-average number of share outstanding:

Basic

173.4

172.7

173.1

172.7

Diluted

173.9

172.7

173.4

172.7

 

Solventum Corporation

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS

(Dollars in millions)

(Unaudited)

September 30,

December 31,

(Millions)

2024

2023

Assets

Current assets

Cash and cash equivalents

$            772

$            194

Accounts receivable — net of allowances of $86 and $82

1,105

1,313

Due from related parties

222

Inventories

Finished goods

529

453

Work in process

181

171

Raw materials and supplies

243

233

Total inventories

953

857

Other current assets

302

155

Total current assets

3,354

2,519

Property, plant and equipment — net

1,599

1,457

Goodwill

6,592

6,535

Intangible assets — net

2,651

2,902

Other assets

549

530

Total assets

$        14,745

$        13,943

Liabilities

Current liabilities

Short-term borrowings and current portion of long-term debt

$            300

$               —

Accounts payable

560

477

Due to related parties

450

Unearned revenue

563

574

Other current liabilities

1,031

677

Total current liabilities

2,904

1,728

Long-term debt

7,809

Pension and postretirement benefits

321

166

Deferred income taxes

214

231

Other liabilities

305

152

Total liabilities

$        11,553

$          2,277

Equity

Common stock par value, $0.01 par value, 750,000,000 shares authorized

$                2

$               —

Shares issued and outstanding – September 30, 2024: 172,754,070

Shares issued and outstanding – December 31, 2023: 0

Additional paid-in capital

3,744

Retained earnings

211

Net parent investment

12,003

Accumulated other comprehensive income (loss)

(765)

(337)

Total equity

3,192

11,666

Total liabilities and equity

$        14,745

$        13,943

 

Solventum Corporation

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS

(Dollars in millions)

(Unaudited)

Nine months ended September 30,

(Millions)

2024

2023

Cash Flows from Operating Activities

Net income

$            448

$          1,074

Adjustments to reconcile net income to net cash provided by operating activities

Depreciation and amortization

405

422

Postretirement benefit plan expense

30

31

Stock-based compensation expense

87

32

Gain on business divestitures

(56)

Deferred income taxes

(93)

(99)

Changes in assets and liabilities

Accounts receivable

14

(24)

Due from related parties

200

Inventories

(99)

(7)

Accounts payable

200

48

Due to related parties

(393)

All other operating activities

167

(53)

Net cash provided by operating activities

966

1,368

Cash Flows from Investing Activities

Purchases of property, plant and equipment

(253)

(202)

Proceeds from sale of business

60

Net cash used in investing activities

(253)

(142)

Cash Flows from Financing Activities

Repayment of debt

(200)

Net transfers to 3M

(8,247)

(1,248)

Proceeds from long-term debt, net of issuance costs

8,303

Other — net

8

2

Net cash used in financing activities

(136)

(1,246)

Effect of exchange rate changes on cash and cash equivalents

1

1

Net increase (decrease) in cash and cash equivalents

578

(19)

Cash and cash equivalents at beginning of year

194

61

Cash and cash equivalents at end of period

$            772

$              42

 

Solventum Corporation

SALES CHANGE ANALYSIS4

(Dollars in millions)

(Unaudited)

Segment and Total Company Net Sales for the First Nine Months*

Nine months ended
September 30,

Increase/(Decrease)

(Dollars in millions)

2024

2023

Total

Currency
Impact

Other

Organic

MedSurg

$         3,463

$        3,464

— %

(0.6) %

(0.5) %

1.1 %

Dental Solutions

979

1,023

(4.3)

(0.6)

(1.9)

(1.8)

Health Information Systems

971

953

1.8

1.8

Purification and Filtration

721

721

0.1

(0.7)

(0.9)

1.7

Corporate and Unallocated5

45

NM

NM

NM

NM

Total Company

$         6,179

$        6,161

0.3 %

(0.5) %

— %

0.8 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

4Total sales change is calculated based on reported sales results. The components of sales change include organic local-currency sales, translation, and other. Organic local-currency sales include both organic volume impacts (which excludes acquisition and divestiture impacts, in addition to supply agreement and impacts) and selling price changes. Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Divestiture impacts include lost sales from the company’s dental anesthetics business that was sold in August 2023 and certain health care businesses retained by 3M India in connection with the spin-off.

5Corporate and Unallocated also includes sales and cost of sales related to products supplied to 3M and other supply agreements related to legacy 3M business and assumed by the company at spin-off.

Solventum Corporation and Subsidiaries
BUSINESS SEGMENTS
(Unaudited)

Operating segments include components of an enterprise where separate financial information is available that is evaluated regularly by the company’s Chief Operating Decision Maker (“CODM”) for the purpose of assessing performance and allocating resources. The company’s CODM is its Chief Executive Officer. The company’s operating activities are managed through four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. There have been no changes to the composition of the segments or to financial information reported within each of the business segments. These segments have been identified based on the nature of the products sold and how the company manages its operations. Transactions among reportable segments are recorded at cost. No operating segments have been aggregated to form reportable segments.

Corporate and Unallocated includes amortization of acquired intangible assets, restructuring and related charges, benefits or costs related to capitalized manufacturing variances, spin-off and separation-related costs and other net costs that the company chose not to allocate directly to its business segments. Spin-off and separation-related costs include any costs incurred as part of our separation from 3M and costs to setup operations as a standalone company, including system implementations, manufacturing relocation, legal entity separation, certain equity awards granted as part of the spin-off, profit mark-ups on transition service arrangements with 3M and other one-time costs. 

Corporate and Unallocated also includes sales and cost of sales related to products supplied to 3M and other supply agreements related to legacy 3M business and assumed by the company at spin-off. Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. Business segment operating income is reconciled to total operating income below:

BUSINESS SEGMENT INFORMATION

Three months ended September 30, 2024

Three months ended September 30, 2023

(Dollars in millions)

Net Sales

Operating
Income

Operating
Margin %

Net Sales

Operating
Income

Operating
Margin %

MedSurg

$      1,182

$         243

20.6 %

$      1,180

$         307

26.0 %

Dental Solutions

313

72

23.0

331

114

34.4

Health Information Systems

326

105

32.2

321

114

35.5

Purification and Filtration

238

20

8.4

242

48

19.8

Total business segment operating income

$         440

$         583

Corporate and Unallocated:

Amortization expense

$         (88)

$         (92)

Other Corporate and Unallocated

(77)

13

Total Corporate and Unallocated

23

(165)

NM

(79)

NM

Total Company

$      2,082

$         275

13.2 %

$      2,074

$         504

24.3 %

BUSINESS SEGMENT INFORMATION

Nine months ended September 30, 2024

Nine months ended September 30, 2023

(Dollars in millions)

Net Sales

Operating
Income

Operating
Margin %

Net Sales

Operating
Income

Operating
Margin %

MedSurg

$      3,463

$         678

19.6 %

$      3,464

$         829

23.9 %

Dental Solutions

979

272

27.8

1,023

349

34.1

Health Information Systems

971

317

32.6

953

304

31.9

Purification and Filtration

721

78

10.8

721

134

18.6

Total business segment operating income

$      1,345

$      1,616

Corporate and Unallocated:

Amortization expense

$       (261)

$       (276)

Other Corporate and Unallocated

(184)

(54)

Total Corporate and Unallocated

45

(445)

NM

(330)

NM

Total Company

$      6,179

$         900

14.6 %

$      6,161

$      1,286

20.9 %

 

Solventum Corporation
SUPPLEMENTAL FINANCIAL INFORMATION
NON-GAAP MEASURES
(Unaudited)

In addition to reporting financial results in accordance with U.S. GAAP, the company use non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. These include (1) Adjusted operating income, and adjusted operating income margin, (2) Adjusted earnings per share, and (3) Free cash flow. Management believes that these non-GAAP financial measures are useful in evaluating current performance and focusing management on our underlying operational results.

There are limitations to the use of the non-GAAP financial measures presented in this information statement. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. Management cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP.

The tables below reconcile our non-GAAP financial measures to the nearest financial measure that is in accordance with U.S. GAAP for the periods presented.

Adjusted Operating Income, Adjusted Operating Income Margin and Adjusted Earnings Per Share (Non-GAAP measures)

Adjusted operating income and adjusted operating income margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, and spin-off and separation-related costs. Adjusted operating income margin is adjusted operating income divided by the U.S GAAP measure total net sales for the same period. The company believes adjusted operating income and adjusted operating income margin provide investors with visibility into the company’s unleveraged, pre-tax operating results and reflects underlying financial performance. However, adjusted operating income should not be construed as inferring that the company’s future results will be unaffected by the items for which the measure adjusts.

Adjusted earnings per share is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, spin-off and separation-related costs, and legal entity restructuring costs. The company believes adjusted earnings per share provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how the company evaluate the business. However, adjusted earnings per share should not be construed as inferring that the company’s future results will be unaffected by the items for which the measure adjusts.

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES – (CONTINUED)*

(Unaudited)

Three months ended September 30, 2024

(Dollars in millions, except per share amounts)

Net sales

Cost of
Sales6

Gross
Margin %

Other
Operating
Expenses7

Operating
Income

Operating
Income
Margin %

Non-
Operating
Expense
(Income),
net8

Income
Before
Income
Taxes

Net Income
Attributable
to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 2,082

$    917

56.0 %

$  1,807

$    275

13.2 %

$    108

$    167

$      122

$   0.70

26.9 %

Non-GAAP Adjustments:

Amortization of acquisition-related intangible assets

(88)

88

4.2

88

73

0.42

Restructuring costs (a)

(1)

(1)

1

0.1

1

1

0.01

Spin-off and separation-related costs (b)

(27)

1.3

(111)

111

5.3

111

85

0.49

Legal entity restructuring (c)

4

0.02

Non-GAAP

$ 2,082

$    889

57.3 %

$  1,607

$    475

22.8 %

$    108

$    367

$      285

$   1.64

22.3 %

Three months ended September 30, 2023

(Dollars in millions, except per share amounts)

Net sales

Cost of
Sales6

Gross
Margin %

Other
Operating
Expenses7

Operating
Income

Operating
Income
Margin %

Non-
Operating
Expense
(Income),
net8

Income
Before
Income
Taxes

Net Income
Attributable
to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 2,074

$    865

58.3 %

$  1,570

$    504

24.3 %

$        4

$    500

$      460

$   2.66

8.0 %

Non-GAAP Adjustments:

Amortization of acquisition-related intangible assets

(92)

92

4.4

92

77

0.45

Restructuring costs (a)

(1)

1

(1)

(1)

(1)

(0.01)

Spin-off and separation-related costs (b)

Gain on business divestitures

56

(56)

(2.7)

(56)

(40)

(0.23)

Non-GAAP

$ 2,074

$    864

58.3 %

$  1,535

$    539

26.0 %

$        4

$    535

$      496

$   2.87

7.3 %

_________

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)    Consists of severance associated with restructuring programs.

(b)    Consists of costs specifically incurred in connection with the separation from 3M.

(c)    Consists of tax impacts for legal entity restructuring in connection with the separation from 3M.

6Cost of sales is the combination of cost of product and cost of software and rental line items from the Condensed Consolidated and Combined Statements of Income and represents the total company cost of sales.

7Other operating expenses is a combination of selling, general and administrative expenses and research and development expenses from the Condensed Consolidated and Combined Statements of Income and represents the total company other operating expenses.

8 Non-operating expense (income), net is the combination of interest expense, net and other expense (income), net line items from the Condensed Consolidated and Combined Statements of Income and represents the total company non-operating expense.

 

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES – (CONTINUED)*

(Unaudited)

Nine months ended September 30, 2024

(Dollars in millions, except per share amounts)

Net sales

Cost of
Sales6

Gross
Margin %

Other
Operating
Expenses7

Operating
Income

Operating
Income
Margin %

Non-
Operating
Expense
(Income),
net8

Income
Before
Income
Taxes

Net Income
Attributable
to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 6,179

$ 2,705

56.2 %

$  5,279

$    900

14.6 %

$    308

$    592

$      448

$   2.58

24.3 %

Non-GAAP Adjustments:

Amortization of acquisition-related intangible assets

(261)

261

4.2

261

218

1.26

Restructuring costs (a)

(5)

0.1

(13)

13

0.2

13

9

0.06

Spin-off and separation-related costs (b)

(48)

0.8

(215)

215

3.5

(38)

253

205

1.18

Legal entity restructuring (c)

35

0.20

Non-GAAP

$ 6,179

$ 2,652

57.1 %

$  4,790

$ 1,389

22.5 %

$    270

$ 1,119

$      915

$   5.28

18.2 %

Nine months ended September 30, 2023

(Dollars in millions, except per share amounts)

Net sales

Cost of
Sales6

Gross
Margin %

Other
Operating
Expenses7

Operating
Income

Operating
Income
Margin %

Non-
Operating
Expense
(Income),
net8

Income
Before
Income
Taxes

Net Income
Attributable
to
Solventum

Diluted
EPS

Effective
Tax Rate

GAAP

$ 6,161

$ 2,626

57.4 %

$  4,875

$ 1,286

20.9 %

$      10

$ 1,276

$   1,074

$   6.22

15.8 %

Non-GAAP Adjustments:

Amortization of acquisition-related intangible assets

(276)

276

4.5

276

231

1.33

Restructuring costs (a)

(12)

0.2

(38)

38

0.6

38

31

0.18

Spin-off and separation-related costs (b)

Gain on business divestitures

56

(56)

(0.9)

(56)

(40)

(0.23)

Non-GAAP

$ 6,161

$ 2,614

57.6 %

$  4,617

$ 1,544

25.1 %

$      10

$ 1,534

$   1,296

$   7.50

15.5 %

__________

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)    Consists of severance associated with restructuring programs.

(b)    Consists of costs specifically incurred in connection with the separation from 3M.

(c)    Consists of tax impacts for legal entity restructuring in connection with the separation from 3M.

6Cost of sales is the combination of cost of product and cost of software and rental line items from the Condensed Consolidated and Combined Statements of Income and represents the total company cost of sales.

7Other operating expenses is a combination of selling, general and administrative expenses and research and development expenses from the Condensed Consolidated and Combined Statements of Income and represents the total company other operating expenses.

8 Non-operating expense (income), net is the combination of interest expense, net and other expense (income), net line items from the Condensed Consolidated and Combined Statements of Income and represents the total company non-operating expense.

Free Cash Flow (non-GAAP measure):

Free cash flow is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The company defines free cash flow as net cash provided by operating activities less purchases of property, plant and equipment. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The company believes free cash flow is meaningful to investors as it is a useful measure of liquidity and the company uses these measures as an indication of the strength of the company and its ability to generate cash. Free cash flow varies across quarters throughout the year. Below find a recap of free cash flow.

(Dollars in millions)

Three months ended
September 30,

Nine months ended
September 30,

Major GAAP Cash Flow Categories

2024

2023

2024

2023

Net cash provided by operating activities

$           169

$           493

$           966

$         1,368

Net cash used in investing activities

(93)

(6)

(253)

(142)

Net cash used in financing activities

(202)

(485)

(136)

(1,246)

Free Cash Flow (non-GAAP measure)

Net cash provided by operating activities

$           169

$           493

$           966

$         1,368

Purchases of property, plant and equipment

(93)

(66)

(253)

(202)

Free cash flow*

76

427

713

1,166

__________________

*         Non-GAAP financial measure.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-reports-third-quarter-2024-financial-results-and-raises-full-year-guidance-302299211.html

SOURCE Solventum

Continue Reading

Technology

Serve Robotics to Acquire Autocado Robot Maker Vebu, Expanding Automation Offering

Published

on

By

Acquisition deepens Serve’s offerings for the restaurant industry, helping partners improve efficiency and manage labor shortage challenges from kitchen to curb

SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ — Serve Robotics Inc. (“Serve”) (Nasdaq: SERV), a leading autonomous robotic delivery company, today announced its agreement to acquire the assets of Vebu Inc. (“Vebu”), a trailblazer in full-stack automation and robotics solutions for restaurant partners. Financial terms of the all-stock transaction were not disclosed.

The acquisition strengthens Serve’s strategic positioning by providing its restaurant partners with a suite of automation solutions and expanding Serve’s offering beyond delivery into back of house automation. Vebu will help Serve become a more integral partner to restaurants, accelerating partner adoption as Serve expands its geographic footprint in new cities across the U.S.

Vebu’s signature robotic product is the Autocado, the pioneering avocado-processing robot which eliminates the need for restaurant workers to spend hours cutting, coring and scooping avocados to prepare guacamole. The Autocado allows employees to load up to 25 pounds of avocados into the device and walk away to focus on serving customers and preparing other items. It is now in pilot testing in Chipotle’s Huntington Beach, Calif. restaurant.

In addition, the transaction is expected to unlock key synergies:

Expanding Partnerships: Vebu’s partnership with leading restaurant companies such as Chipotle will extend Serve’s existing business relationships, which include Shake Shack and 7-Eleven, among others.Expanding Serve’s Market Opportunity: This acquisition complements Serve’s recent expansion into delivery over all distances through its partnership with Alphabet’s Wing Aviation subsidiary, making Serve one of the most comprehensive automation providers in the restaurant industry.

Vebu’s founder and CEO Buck Jordan will join Serve Robotics as SVP of Kitchen Automation. He will continue to lead the Vebu team, overseeing Autocado’s continued development and driving additional innovations on the product roadmap. Mr. Jordan, a serial entrepreneur who previously founded Miso Robotics, brings deep expertise and connections in kitchen automation. His experience in the sector, combined with Vebu’s innovation, will bolster Serve’s ability to address the labor shortages faced by the restaurant industry.

“By adding Vebu’s pioneering kitchen automation capabilities to our autonomous delivery offering, we are uniquely positioned to utilize robotics and AI to solve the labor shortages plaguing the restaurant industry. This acquisition underscores our commitment to helping our partners operate more efficiently and to expanding our partnerships with national chain restaurants like Chipotle. We are thrilled to be joined by an accomplished team pioneering an innovative technology, operating as a separate business unit within our organization,” said Dr. Ali Kashani, CEO and co-founder of Serve Robotics.

Buck Jordan, founder and CEO of Vebu, commented, “I am thrilled to join the Serve Robotics team, which I have known and supported since the early days as an investor. This is an exciting opportunity to merge our expertise and bring groundbreaking automation to a wider audience. Together, we will provide a suite of automation solutions that will change the future of restaurant operations.”

Vebu joins Serve with a balance sheet that supports its operations to complete its pilot with Chipotle. This acquisition strengthens Serve’s core business and long-term strategy to be a leader in restaurant automation.

About Serve Robotics

Serve develops advanced, AI-powered, low-emissions sidewalk delivery robots that endeavor to make delivery sustainable and economical. Spun off from Uber in 2021 as an independent company, Serve has completed tens of thousands of deliveries for enterprise partners such as Uber Eats and 7-Eleven. The company has scalable multi-year contracts, including a signed agreement to deploy up to 2,000 delivery robots on the Uber Eats platform across multiple U.S. markets.

For further information about Serve Robotics (Nasdaq:SERV), visit www.serverobotics.com or follow us on social media via X (Twitter), Instagram, or LinkedIn @serverobotics.

About Vebu Inc.

Vebu is a full stack Automation, Robotics, and Intelligence company focused on building technology solutions for and with the broad food industry. With a partner driven team of experts spanning engineering, robotics, artificial intelligence, and product development, Vebu is building products to help humans do more. For further information, visit vebulabs.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Serve intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act. These forward-looking statements can be about future events, including statements regarding Serve’s intentions, objectives, plans, expectations, assumptions and beliefs about future events, including Serve’s expectations with respect to the financial and operating performance of its business, its capital position, and future growth. The words “anticipate”, “believe”, “expect”, “project”, “predict”, “will”, “forecast”, “estimate”, “likely”, “intend”, “outlook”, “should”, “could”, “may”, “target”, “plan” and other similar expressions can generally be used to identify forward-looking statements. Indications of, and guidance or outlook on, future earnings or financial position, performance, or outcomes from our planned acquisition described in this press release are also forward-looking statements. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Serve’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the “SEC”) and in its subsequent filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Serve undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact

Media
Aduke Thelwell, Head of Communications & Investor Relations
Serve Robotics
press@serverobotics.com

Investor Relations
investor.relations@serverobotics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/serve-robotics-to-acquire-autocado-robot-maker-vebu-expanding-automation-offering-302299328.html

SOURCE Serve Robotics Inc.

Continue Reading

Trending